DNA synthesis, mismatch repair and cancer (review)

International Journal of Oncology

Volumn 12, Issue 2, 1998, Pages 377-382

  Hoffmann, Jean Sébastien ^a   Cazaux, Christophe ^a  

^a INSTITUT DE PHARMACOLOGIE ET DE BIOLOGIE STRUCTURALE   (France)

Author keywords

DNA polymerase; DNA precursors; Mismatch repair; Mutator phenotype

Indexed keywords

DNA POLYMERASE;

BASE MISPAIRING; CANCER DIAGNOSIS; DNA METABOLISM; DNA REPLICATION; DNA SYNTHESIS; GENE MUTATION; GENETIC STABILITY; GENOME; MUTATION RATE; MUTATOR GENE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; REVIEW; TANDEM REPEAT;

BASE PAIR MISMATCH; COLONIC NEOPLASMS; DNA; DNA REPAIR; DNA, RECOMBINANT; DNA-BINDING PROTEINS; DNA-DIRECTED DNA POLYMERASE; HUMANS; MUTAGENESIS; NUCLEOTIDES; PURINE NUCLEOTIDES; RIBONUCLEOTIDE REDUCTASES;

EID: 0031933194     PISSN: 10196439     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (79)

1. Loeb LA: Mutator phenotype may be required for multistage carcinogenesis. Cancer Res 51: 3075-3079, 1991.
2. Marra G and Boland CR: Hereditary nonpolyposis colorectal cancer (HNPCC): the syndrome, the genes and historical perspectives. J Natl Cancer Inst 87: 1114-1125, 1995.
3. Balaban GB, Herlyn M, Clark WH Jr and Nowell PC: Karyotypic evolution in human malignant melanoma. Cancer Genet Cytogenet 19: 113-122, 1986.
4. James CD, Carlbom E, Dumanski JB, Hansen M, Nordenskjold M, Collins VP and Cavenee WK: Clonal genomics alterations in glioma malignancy stages. Cancer Res 48: 5546-5551, 1988.
5. Loeb LA: Microsatellite instability: marker of a mutator phenotype in cancer. Cancer Res 54: 5059-5063, 1994.
6. Peinado MA, Malkhosyan S, Velasquez A and Perucho M: Isolation and characterization of allelic losses and gains in colorectal tumors by arbitrarily primed polymerase chain reactions. Proc Natl Acad Sci USA 89: 10065-10069, 1992.
7. Bhattacharyya NP, Skandalis A, Ganesh A, Groden J and Meuth M: Mutator phenotypes in human colorectal carcinoma cell lines. Proc Natl Acad Sci USA 91: 6319-6323, 1994.
8. Sakamoto S, Sagara T, Iwama T, Kawasaki T and Okamoto R: Increased activities of thymidine kinase isozymes in human colon polyp and carcinoma. Carcinogenesis 6: 917-919, 1985.
9. Sakamoto S, Kuxa K, Tsukada K, Sagara T, Kasahara N and Okamoto R: Relative activities of thymidylate synthetase and thymidine kinase in 1,2-dimethylhydrazine-induced colon carcinomas in rats. Carcinogenesis 8: 405-408, 1987.
10. Luccioni C, Beaumatin J, Bardot V and Lefrançois D: Pyrimidine nucleotide metabolism in human colon carcinomas: comparison of normal tissues, primary tumors and xenografts. Int J Cancer 58: 517-522, 1994.
11. Herzfeld A and Raper SM: Relative activities of thymidylate synthetase and thymidine kinase in rat tissues. Cancer Res 40: 744-750, 1980.
12. Dutrillaux B and Muleris M: Induction of increased salvage pathways of nucleotide synthesis by dosage effect due to chromosome imbalances may be fundamental in carcinogenesis: the example of colorectal carcinoma. Ann Genet 29: 11-15, 1986.
13. Boer P and Sperling O: Role of cellular ribose-5-phosphate content in the regulation of 5-phosphoribosyl-1-pyrophosphate and de novo purinc synthesis in a human hepatoma cell line. Metabolism 44: 1469-1474, 1995.
14. Bardot V, Dutrilaux AM, Dclattrc JY, Vega F, Poisson M, Dutrillaux B and Luccioni C: Purine and pyrimidine metabolism in human gliomas: relation to chromosomal aberrations. Br J Cancer 70: 212-218, 1994.
15. Xie KC and Plunkett W: Deoxynucleotide pool depletion and sustained inhibition of ribonucleotide recluctase and DNA synthesis after treatment of human lymphoblastoid cells with 2-chloro-9-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl) adenine. Cancer Res 56: 3030-3037, 1996.
16. Dorr RT and von Hoff DD: Cancer chemotherapy handbook. White J and Davis K (eds). Appleton & Lange, Norwalk, Connecticut, 1994.
17. Pillwein K, Chiba P, Knoflach A, Czermak B, Schuchter K, Gersdorf E, Ausserer B, Murr C, Goebl R and Stockhammer G: Purine metabolism of human glioblastoma in vivo. Cancer Res 50: 1576-1579, 1990.
18. Sanfilippo O, Camici M, Tozzi MG, Turriani M, Faranda A, Ipata PL and Silvestrini R: Relationship between the levels of purine salvage pathway enzyme and clinical/biological aggressiveness of human colon carcinoma. Cancer Biochem Biophys 14: 57-66, 1994.
19. Camici M, Tozzi MG, Allegrini S, del Corso A, Sanfilippo O, Daidone MG, de Marco C and Ipata PL: Purine salvage enzyme activities in normal and neoplastic human tissues. Cancer Biochem Biophys 11: 201-209, 1990.
20. Ebuchi M, Sakamoto S, Kudo H, Nagase J and Endo M: Clinicopathological stages and pyrimidine nucleotide synthesis in human mammary carcinomas. Anticancer Res 15: 1481-1484, 1995.
21. Al NI, Takamiya Y, Voloshin Y, Dritschilo A, Martuza RL and Jorgensen TJ: Expression of thymidine kinase is essential to low dose radiation resistance of rat glioma cells. Cancer Res 54: 5614-5617, 1994.
22. Sakamoto S, Ebuchi M and Iwama T: Relative activities of thymidylate synthetase and thymidine kinase in human mammary tumours. Anticancer Res 13: 205-207, 1993.
23. Culver KW, Ram Z, Wallbridge S, Ishii H, Oldfield EH and Blaese RM: In vivo gene transfer with retroviral vector-producer cells for treatment of experimental brain tumors. Science 256: 1550-1552, 1992.
24. Caruso M, Panis Y, Gagandeep S, Houssin D, Salzmann JL and Klatzmann D: Regression of established macroscopic liver metastases after in situ transduction of a suicide gene. Proc Natl Acad Sci USA 90: 7024-7028, 1993.
25. Ezzeddine ZD, Martuza RL, Platika D, Short MP, Malick A, Choi B and Breakefield XO: Selective killing of glioma cells in culture and in vivo by retrovirus transfer of the herpes simplex virus thymidine kinase gene. New Biol 3: 608-614, 1991.
26. Huber BE, Richards CA and Krenitsky TA: Retroviral-mediated gene therapy for the treatment of hepatocellular carcinoma: an innovative approach for cancer therapy. Proc Natl Acad Sci USA 88: 8039-8043, 1991.
27. Moolten FL: Tumor chemosensitivity conferred by inserted herpes thymidine kinase genes: paradigm for a prospective cancer control strategy. Cancer Res 50: 7820-7825, 1986.
28. Cazaux C, Tiraby M, Loubiere L, Haren L, Klatmann D and Tiraby G: Phosphorylation and cytotoxicity of therapeutic nucleoside analogues: a comparison of alpha and gamma herpesvirus thymidine kinase suicide genes. Cancer Gene Ther (In press).
29. Kenne K and Akerbloom L: Deoxyribonucleoside triphosphate pool levels in three cell strains of human chromosome instability syndromes: ataxia telangiectasia (GM2052), Bloom's syndrome (GM 1492) and Fanconi's anemia (GM368). Cancer Biochem Biophys 11: 69-77, 1990.
30. Shiraishi Y: Effects of cell fusion and deoxynucleosides on sister-chromatid exchanges in B-lymphoblastoid cell lines from Bloom's syndrome patients. Mutat Res 199: 75-83, 1988.
31. Shiraishi Y, Taguchi T, Ozawa M and Bamezai R: Different mutations responsible for the elvated sister-chromatid exchange frequencies in Bloom syndrome and X-radiatcd B-lymphoblastoid cell lines originating from acute leukemia. Mutat Res 211: 272-278, 1989.
32. Glinos AD and Warren KR: Nonproliferating neoplastic cells in culture: behavior of the adenine nucleotides. J Natl Cancer Inst 62: 819-823, 1979.
33. Kunz BA, Kohalmi SE, Kunkel TA, Mathews CK and McIntosh EM: Deoxyribonucleoside triphosphate levels: a critical factor in the maintenance of gene stability. Mutat Res 318: 1-64, 1994.
34. Cohen A and Thomson E: DNA repair in nondividing human lymphocytes: inhibition by deoxyadenosine. Cancer Res 46: 1585-1588, 1986.
35. Kunkel TA: Biological asymmetries and the fidelity of eukaryotic DNA replication. Bioessays 14: 303-308, 1992.
36. Phear G and Meuth M: The genetic consequences of DNA precursor pool imbalance: sequence analysis of mutations induced by excess thymidine at the hamster aprt locus. Mutat Res 214: 201-206, 1989.
37. Minnick DT and Kunkel TA: DNA synthesis errors, mutations and cancer. Cancer Surv 28: 3-20, 1997.
38. Koyama H, Ayusawa D, Tsuji M and Seno T: Thymidineless death and mutation induction in cultured FM3A cell mutants deficient in thymidylate synthase. Mutat Res 105: 433-438, 1982.
39. Kresnak MT and Davidson RL: Thymidine-induced mutations in mammalian cells: sequence specificity and implications for mutagenesis in vivo. Proc Natl Acad Sci USA 89: 2829-2833, 1992.
40. Rossman TG and Stone-Wolff DS: Inhibition of DNA synthesis is not sufficient to cause mutagenesis in Chinese hamster cells. Biochimie 64: 809-810, 1982.
41. Mattano SS, Palella TD and Mitchell BS: Mutations induced at the hypoxanthine-guanine phosphoribosyltransferase locus of human T-lymphoblasts by perturbations of purine deoxyribonucleoside triphosphate pools. Cancer Res 50: 4566-4571, 1990.
42. Bouayadi K, Hoffmann JS, Fons P, Tiraby M, Reynes JP and Cazaux C: Overexpression of DNA polymerase β sensitizes mammalian cells to 2',3'-dideoxyxytidine and 3'-azido-3'-deoxythymidine. Cancer Res 57: 110-116, 1997.
43. Friedman HS, Dolan ME, Kaufmann SH, Colvin OM, Griffith OW, Moschel RC, Schold SC, Bigner DD and Ali-Osman F: Elevated DNA polymerase alpha, DNA polymerase beta, and DNA toposisomerase II in a melphalan-resistant rhabdomyosarcoma xenograpft that is cross-resistant to nitrosoureas and topotecan. Cancer Res 54: 3487-3493, 1994.
44. Ohno Y, Spriggs D, Matsukage A, Ohno T and Kufe D: Effects of 1-β-D-arabinofuranosylcytosine incorporation on elongation of specific sequences by DNA polymerase β. Cancer Res 48: 1494-1498, 1988.
45. Hoffmann JS, Pillaire MJ, Garcia-Estefania D, Lapalu S and Villani G: In vitro bypass replication of the cisplatin-d(GpG) lesion by calf thymus DNA polymerase β and human immunodeficiency virus type I reverse transcriptase is highly mutaenic. J Biol Chem 271: 15386-15392, 1996.
46. Hoffmann JS, Pillaire MJ, Maga G, Podust V, Hübscher U and Villani G: DNA polymerase β bypass in vitro d(GpG)-cisplatin adduct placed on codon 13 of H-ras gene. Proc Natl Acad Sci USA 92: 5356-5360, 1995.
47. Dobashi Y, Shuin T, Tsuruga H, Uemura H, Soichiro T and Yoshinobu K: DNA Polymerase β gene mutation in human prostate cancer. Cancer Res 54: 2827-2829, 1994.
48. Wang L, Patel U, Ghosh L and Banerjee S: DNA polymerase β mutations in human colorectal cancer. Cancer Res 52: 4824-4827, 1992.
49. Matsuzaki J, Dobashi Y, Miyamoto H, Ikeda I, Fujinami K, Shuin T and Kubota Y: DNA polymerase β gene mutations in human bladder cancer. Mol Carcinog 15: 38-43, 1996.
50. Bhattacharyya N and Banerjee S: A variant of DNA polymerase β acts as a dominant negative mutant. Proc Natl Acad Sci USA 94: 10324-10329, 1997.
51. Da Costa LT, Liu B, El-Deiry W, Hamilton SR, Kinzler KW, Vogelstein B, Markowitz S, Willson JK, de la Chapelle A and Downey KM: Polymerase delta variants in RER colorectal tumours. Nat Genet 9: 10-11, 1995.
52. Schaaper RM, Kunkel TA and Loeb LA: Infidelity of DNA synthesis associated with bypass of apurinic sites. Proc Natl Acad Sci USA 80: 487-491, 1983.
53. Tkeshelashvili LK, McBride T, Spence K and Loeb LA: Mutation spectrum of cooper-induced DNA damage. J Biol Chem 266: 6401-6406, 1991.
54. Modrich P and Lahue R: Mismatch repair in replication fidelity, genetic recombination, and cancer biology. Annu Rev Biochem 65: 101-133, 1996.
55. Thomas DC, Roberts JD and Kunkel TA: Heteroduplex repair in extracts of human HeLa cells. J Biol Chem 266: 3744-3751, 1991.
56. Holmes J Jr, Clark S and Modrich P: Strand-specific mismatch correction in nuclear extracts of human and Drosophila melanogaster cell lines. Proc Natl Acad Sci USA 87: 5837-5841, 1990.
57. Jiricny J: Mismatch repair and cancer. Cancer Surv 28: 47-68, 1996.
58. Palombo F, Iaccarino I, Nakajima E, Ikejima M, Shimada T and Jiricny J: hMutS-beta, a heterodimer of HMSH2 and HMSH3, binds to insertion/deletion loops in DNA. Curr Biol 6: 1181-1184, 1996.
59. Drummond JT, Li GM, Longley MJ and Modrich P: Isolation of an hMSH2-p160 heterodimer that restores DNA mismatch repair to tumor cells. Science 268: 1909-1912, 1995.
60. Finlay GJ: Genetics, molecular biology and colorectal cancer. Mutat Res 290: 3-12, 1993.
61. Fearon ER and Vogelstein B: A genetic model for colorectal mutagenesis. Cell 61: 759-767, 1990.
62. Baker SM, Bronner CE, Zhang L, Plug AW, Robatzek M, Warren G, Elliott EA, Yu J, Ashley T, Arnheim N, Flavell RA and Liskay RM: Male mice defective in the mismatch repair gene PMS2 exhibit abnormal synapsis in meiosis. Cell 82: 309-319, 1995.
63. De Wind N, Dekker M, Berns A, Radman M and Te Riele H: Inactivation of the mouse Msh2 gene results in mismatch repair deficiency, methylation, hyperrecombination, and predisposition to cancer. Cell 82: 321-330, 1995.
64. Reitmair AH, Schmits R, Ewel A, Bapat B, Redston M, Mitri A, Waterhouse P, Mittrucker HW, Wakeham A and Liu B: MSH2 deficient mice are viable and susceptible to lymphoid tumours. Nat Genet 11: 64-70, 1995.
65. Ionov Y, Peinado MA, Malkhosyan S, Shibata D and Perucho M: Ubiquitous somatic mutations in simple repeated sequences reveal a new mechanism for colonic carcinogenesis. Nature 363: 558-561, 1993.
66. Thibodeau SN, Bren G and Scheid D: Microsatellite instability in cancer of the proximal colon. Science 260: 816-819, 1993.
67. Mellon I, Rajpal DK, Koi M, Boland CR and Champe GN: Transcription-coupled repair deficiency and mutations in human mismatch repair genes. Science 272: 557-560, 1996.
68. Li GM, Wang H and Romano LJ: Human MutS specifically binds to DNA containing aminofluorene and acetylaminofluorene adducts. J Biol Chem 271: 24084-24088, 1996.
69. Duckett DR, Drummond JT, Murchie AIH, Reardon JT, Sancar A, Lilley DM and Modrich P: Human MutS recognizes damaged DNA base pairs containing O6-methylguanine, O4-methylthymine, or the cisplatin-d(GpG)adduct. Proc Natl Acad Sci USA 93: 6443-6447, 1996.
70. Loeb LA: Transient expression of a mutator phenotype in cancer cells. Science 277: 1449-1450, 1997.
71. Richards B, Zhang H, Phear G and Meuth M: Conditional mutator phenotypes in hMSh2-deficient tumor cell lines. Science 277: 1523-1526, 1997.
72. Foster PL and Cairns J: Mechanisms of directed mutation. Genetics 131: 783-789, 1992.
73. Torkelson J, Harris RS, Lombardo MJ, Nagendran J, Thulin C and Rosenberg SM: Genome-wide hypermutation in a subpopulation of stationary-phase cells underlies recombination-dependent adaptative mutation. EMBO J 16: 3303-3311, 1997.
74. Plug AW, Clairmont CA, Sapi E, Ashley T and Sweasy JB: Evidence for a role of DNA polymerase β in mammalian meiosis. Proc Natl Acad Sci USA 94: 1327-1331, 1997.
75. Baumann P, Benson FE and West SC: Human Rad51 protein promotes ATP-dependent homologous pairing and strand transfer reactions in vitro. Cell 87: 757-766, 1996.
76. Sharan SK, Morimatsu M, Albrecht U, Lim DS, Regel E, Sinh C, Sands A, Eichele G, Hasty P and Bradley A: Embryonic lethality and radiation hypersensitivity mediated by Rad51 in mice lacking BRCA2. Nature 386: 804-810, 1997.
77. Scully R, Chen J, Plug A, Xiao Y, Weaver D, Feunteun J, Ashley T and Livingston DM: Association of BRCA1 with Rad51 in mitotic and meiotic cells. Cell 88: 265-275, 1997.
78. Roberts JD and Kunkel TA: Fidelity of DNA replication. In: DNA Replication in Eukaryotic Cells. Cold Spring Harbor Laboratory (In press).
79. Kornberg A and Baker TA: DNA replication. Freeman WH and Company, New York, 1992.